ClinicalTrials.gg
Status unknownNCT01521819Updated Oct 25, 2012

Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration

An interventional study of Iray and Lucentis in Retinal Pigment Epithelial Detachment With Vascularization and Age Related Macular Degeneration, sponsored by Oraya Therapeutics, Inc.. Status unknown at 1 site in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.

Sponsored by Oraya Therapeutics, Inc. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2012), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Planned enrollment
113th of 124
12 · median 64
Started
2012
with 6 others
No phase
12 of 125
none open now
Registered
68th of 125
by date

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 113th largest by planned enrollment of the 124 interventional ones that give a count, is one of 7 that started in 2012, is one of 12 with no phase, and was the 68th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This is a pilot, single-center, interventional clinical trial in which subjects will receive 16 Gy of IRay treatment and Lucentis, followed by Lucentis treatment as needed.

Read the detailed description

This study will evaluate the efficacy of IRay treatment in patients with Vascularized Pigment Epithelial Detachment (V-PED) with serous component superior to 50% of the lesion as determined by decreasing the lesion activity; by decreasing the number of Lucentis injections required during the 12 month study.

03

Conditions studied

  • Retinal Pigment Epithelial Detachment With Vascularization
  • Age Related Macular Degeneration

Keywords

  • AMD
  • V-Ped
  • Vascularized Pigment Epithelial Detachment
  • Iray
  • radiation
  • retina
  • macula
  • radiotherapy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with V-PED with serous component comprising greater than 50% of the lesion area, naïve or previously treated with Lucentis® injections and Photodynamic therapy (PDT) using VisudyneÒ.
  • Must have a total lesion size of \< 12 disc areas and a lesion with the greatest linear dimension of \< 6 mm, but not greater than 3 mm from the center of the fovea to the furthest point on lesion perimeter.
  • The distance from the center of the fovea to the nearest edge of the optic disc should be not less than 3 mm. (This distance is confirmed by Oraya software prior to treatment.).
  • Must have provided , documented it in writing, and have been given a copy of the signed informed consent form.
  • Must be willing and able to return for scheduled treatment and follow-up examinations for the 1-year duration of the study.
  • Must be at least 50 years of age.
  • Women must be ≥ 1 year or surgically sterilized, or a pregnancy screen must be performed prior to the study and a reliable form of , approved by the investigator, must be maintained during the study.
  • Must have best corrected visual acuity of 75 to 25 letters (inclusive) in the study eye and at least 20 letters in the fellow eye (if both eyes meet all the study criteria, then the eye with the worst vision should be selected as the study eye).

Exclusion criteria

Exclusion Criteria

  • CNV due to causes other than AMD, including ocular histoplasmosis syndrome, angioid streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia (spherical equivalent _-8 diopters).
  • A globe axial length of \< 20 mm or > 26 mm.
  • Evidence of diabetes or with retinal findings consistent with diabetic retinopathy or retinopathy for any cause.
  • Hypertension that is not controlled with anti-hypertensive medication.
  • Prior or concurrent therapies for age related macular degeneration including submacular surgery, subfoveal thermal laser photocoagulation (with or without photographic evidence), or transpupillary thermotherapy (TTT).
  • History of radiation to the head in the region of the study eye.
  • Previous posterior vitrectomy at any time, YAG capsulotomy or cataract surgery within 3 months, or any other surgery in the study eye within 6 months prior to the screening visit.
  • Intravitreal device in the study eye.
  • Concomitant disease in the study eye which might interfere with the effect of assessment of the study treatment, including uveitis, acute ocular or periocular infection, retinal vasculopathies (including retinal vein occlusions, etc.) or intraocular pressure > 30 mmHg uncontrollable with medications.
  • History of rhegmatogenous retina detachment, optic neuritis or intraocular tumors in the study eye.
  • Inadequate pupillary dilation, significant media opacities, or other conditions in the study eye, including cataract, which may interfere with visual acuity or the evaluation of the posterior segment. Subjects likely to need cataract surgery during the 1 year study period should also not be enrolled.
  • Known serious allergies to fluorescein dye used in angiography.
  • Subjects must not have subretinal hemorrhage or Retinal Pigment Epithelium tear involving the center of the foveal avascular zone.
  • Known sensitivity or allergy to Lucentis, or any other drug used in the study, such as topical anesthetic, cycloplegic mydriatics, or lubricating eye gel.
  • or sensitivity to contact lens application (i.e. corneal dystrophies and recurrent corneal erosions).
  • Currently receiving chemotherapy, having completed a course within the 90 days preceding study enrollment, or expecting to begin chemotherapy while participating in the study.
  • Current participation in another drug or device clinical trial.
  • History of use of drugs with known retinal toxicity, including: chloroquine (Aralen - antimalarial), hydroxychloriquine (Plaquenil - antimalarial), phenothiazines (Thorazine, Stelazine, Mellaril, Prolixin, Trilafon, etc., - tranquilizing antipsychotic medications) and these patients are exhibiting signs of retinal toxicity.
  • Concurrent use of systemic anti-VEGF agents.
  • Any other condition, which in the judgment of the investigator would prevent the subject from granting consent or completing the study, such as dementia, mental illness (including generalized anxiety disorder, claustrophobia, etc.), or inability to position in the device (due to musculoskeletal problems, etc.).
  • History of other significant, uncontrolled disease including cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal, metabolic dysfunction, any clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of intravitreal ranibizumab or that might affect interpretation of the results of the study or render the subject at high risk for treatment complication.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Iray plus Lucentis

    open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.

    Radiation: Iray · Drug: Lucentis

Interventions

  • RadiationIray

    The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.

  • Intravitreal injection of Lucentis as needed.

06

What researchers measure

Primary outcomes

  1. Lesion change as measured with fluorescein angiography.

    Change in the proportion of the lesion which is active at 12 months.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Number of Lucentis injections

    Number of Lucentis injections during 12 months

    Time frame: Baseline and 12 months

  2. Visual Acuity change

    Mean change in visual acuity

    Time frame: Baseline and 12 months

07

Study locations

1 site
  • Università Vita-Salute Istituto Scientifico San Raffaele
    Milano, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Aug 2013 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2012
First posted
Jan 31, 2012
Start
Aug 2012
Primary completionEst.
Aug 2013
CompletionEst.
Aug 2014
Last update
Oct 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01521819
Lead sponsor
Oraya Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 31, 2012
Start date
Aug 2012
Primary completion
Aug 2013 (estimated)
Completion
Aug 2014 (estimated)
Last update
Oct 25, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion